Market Place
Sourcing Support
aTyr`s Efzofitimod To Be Featured At CHEST 2024 Annual Meeting
08 Oct 2024 //
GLOBENEWSWIRE
aTyr Pharma Publishes Efzofitimod in Pulmonary Sarcoidosis
02 Oct 2024 //
GLOBENEWSWIRE
aTyr Pharma to Participate in September Investor Conferences
21 Aug 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
aTyr Pharma Appoints Jayant Aphale As VP Of Technical Operations
06 Aug 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Research Study with Stanford Medicine
30 Jul 2024 //
GLOBENEWSWIRE
ATYR Pharma Completes Enrollment For Phase 3 Efzofitimod Trial
22 Jul 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
03 Jun 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 May 2024 //
GLOBENEWSWIRE
aTyr To Present Efzofitimod Mechanism Of Action Poster At ATS 2024
15 May 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Positive DSMB Review For Efzofitimod Phase 3
14 May 2024 //
GLOBENEWSWIRE
aTyr Pharma to Present at Upcoming Investor Conferences
06 May 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
02 May 2024 //
GLOBENEWSWIRE
aTyr Pharma to Participate in April Investor Conferences
01 Apr 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results
14 Mar 2024 //
GLOBENEWSWIRE
aTyr to Webcast Conference Reporting Q4 and Full Year End 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces EAP for EFZO-FIT¢ Clinical Trial Participants
21 Feb 2024 //
GLOBENEWSWIRE
aTyr to Present Posters Highlighting Importance of Neuropilin-2
29 Jan 2024 //
GLOBENEWSWIRE
aTyr Pharma Announces Emeritus Dr. Wayne A. I. Frederick as Advisor
18 Jan 2024 //
GLOBENEWSWIRE
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod
13 Nov 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
09 Nov 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present at November Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Dosing of First Patient in Phase 2 Study of Efzofitimod
31 Oct 2023 //
GLOBENEWSWIRE
aTyr Presents Efzofitimod Data Showing Improvements in Patient Reported Outcomes
11 Sep 2023 //
GLOBENEWSWIRE
aTyr to Present at the H.C. Wainwright 25th Annual Global Investment Conference
24 Aug 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
09 Aug 2023 //
GLOBENEWSWIRE
European Commission Grants Orphan Drug Desig. for aTyr Pharma™s Efzofitimod
22 Jun 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod
20 Jun 2023 //
GLOBENEWSWIRE
aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research
06 Jun 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference
25 May 2023 //
GLOBENEWSWIRE
aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action
22 May 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present at 2023 RBC Capital Markets Global Healthcare Conference
11 May 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update
09 May 2023 //
GLOBENEWSWIRE
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810
17 Apr 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces First Major Review Article for Efzofitimod Published
30 Mar 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present Data Identifying Fibrosis Target for ATYR0101
21 Mar 2023 //
GLOBENEWSWIRE
aTyr and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting
20 Mar 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results
09 Mar 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present at March Investor Conferences
08 Mar 2023 //
GLOBENEWSWIRE
aTyr Pharma to Webcast Conference Call Reporting Q4 Financial Results
02 Mar 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with (SSc-ILD)
01 Mar 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Pricing of Public Offering of Common Stock
09 Feb 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces Commencement of Public Offering of Common Stock
08 Feb 2023 //
GLOBENEWSWIRE
aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod
31 Jan 2023 //
GLOBENEWSWIRE
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone
19 Jan 2023 //
GLOBENEWSWIRE
EC Grants Orphan Drug Designation for aTyr Pharma`s Efzofitimod for Sarcoidosis
18 Jan 2023 //
GLOBENEWSWIRE
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
15 Dec 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
10 Nov 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Publication of +VE Data Ph 1b/2a of Efzofitimod
09 Nov 2022 //
GLOBENEWSWIRE
aTyr to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
03 Nov 2022 //
GLOBENEWSWIRE
aTyr Pharma to Present at the Jefferies London Healthcare Conference
25 Oct 2022 //
GLOBENEWSWIRE
aTyr Announces Research Collaboration with Dualsystems Biotech AG
12 Oct 2022 //
GLOBENEWSWIRE
aTyr Pharma to Participate in RBC Biotech Expert Insights Pulmonary/Lung Disease
04 Oct 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin
29 Sep 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™
27 Sep 2022 //
GLOBENEWSWIRE
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for SSc-ILD
14 Sep 2022 //
PRESS RELEASE
aTyr Pharma to Present at the H.C. Wainwright 24th AnnualGIC 2022
06 Sep 2022 //
GLOBENEWSWIRE
aTyr Pharma to Present Poster at the European Respiratory Society (ERS)
01 Sep 2022 //
GLOBENEWSWIRE
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
15 Aug 2022 //
GLOBENEWSWIRE
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923)
11 Aug 2022 //
GLOBENEWSWIRE
